Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
Palvella Therapeutics (NASDAQ:PVLA), a clinical-stage biopharmaceutical company developing therapies for rare genetic skin diseases, has announced upcoming presentations at two major healthcare investor conferences. CEO Wes Kaupinen will present at the Cantor Global Healthcare Conference on September 4, 2025, at 2:45 PM ET and the H.C. Wainwright Global Investment Conference on September 8, 2025, at 10:30 AM ET.
The presentations will be accessible via live webcast on Palvella's website, with replays available for approximately 90 days afterward.
Palvella Therapeutics (NASDAQ:PVLA), societ脿 biofarmaceutica in fase clinica che sviluppa terapie per rare malattie genetiche della pelle, ha annunciato partecipazioni a due importanti conferenze per investitori nel settore sanitario. L鈥檃mministratore delegato Wes Kaupinen terr脿 una presentazione al Cantor Global Healthcare Conference il 4 settembre 2025 alle 14:45 ET e al H.C. Wainwright Global Investment Conference l'8 settembre 2025 alle 10:30 ET.
Le presentazioni saranno trasmesse in diretta via webcast sul sito di Palvella e le registrazioni saranno disponibili in replay per circa 90 giorni successivi.
Palvella Therapeutics (NASDAQ:PVLA), una compa帽铆a biofarmac茅utica en fase cl铆nica que desarrolla terapias para raras enfermedades gen茅ticas de la piel, ha anunciado presentaciones pr贸ximas en dos importantes conferencias para inversores en salud. El CEO Wes Kaupinen presentar谩 en la Cantor Global Healthcare Conference el 4 de septiembre de 2025 a las 2:45 PM ET y en la H.C. Wainwright Global Investment Conference el 8 de septiembre de 2025 a las 10:30 AM ET.
Las presentaciones se podr谩n ver en webcast en directo en la web de Palvella y las repeticiones estar谩n disponibles durante aproximadamente 90 d铆as despu茅s.
Palvella Therapeutics (NASDAQ:PVLA)電� 頋穩 鞙犾爠靹� 頂茧秬歆堩櫂 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎届偓搿�, 欤检殧 項姢旒�鞏� 韴瀽鞛� 旖橅嵓霟办姢鞐愳劀鞚� 氚滍憸 鞚检爼鞚� 氚滍憸頄堨姷雼堧嫟. 斓滉碃瓴届榿鞛� 鞗姢 旃挫毎頂茧劏(Wes Kaupinen)鞚� 2025雲� 9鞗� 4鞚� Cantor Global Healthcare Conference鞐愳劀 霃欕秬鞁滉皠 旮办 鞓ろ泟 2鞁� 45攵勳棎, 攴鸽Μ瓿� 2025雲� 9鞗� 8鞚� H.C. Wainwright Global Investment Conference鞐愳劀 霃欕秬鞁滉皠 旮办 鞓れ爠 10鞁� 30攵勳棎 氚滍憸頃╇媹雼�.
氚滍憸電� Palvella 鞗轨偓鞚错姼毳� 韱淀暅 霛检澊敫� 鞗轨簮鞀ろ姼搿� 鞁滌箔頃� 靾� 鞛堨溂氅�, 鞎� 90鞚缄皠 鞛儩(毽攲霠堨澊)霃� 鞝滉车霅╇媹雼�.
Palvella Therapeutics (NASDAQ:PVLA), une soci茅t茅 biopharmaceutique en phase clinique d茅veloppant des traitements pour des maladies g茅n茅tiques rares de la peau, a annonc茅 ses prochaines interventions lors de deux grandes conf茅rences pour investisseurs en sant茅. Le directeur g茅n茅ral Wes Kaupinen prendra la parole lors de la Cantor Global Healthcare Conference le 4 septembre 2025 脿 14h45 ET et lors de la H.C. Wainwright Global Investment Conference le 8 septembre 2025 脿 10h30 ET.
Les pr茅sentations seront accessibles en webcast en direct sur le site de Palvella, avec des rediffusions disponibles pendant environ 90 jours ensuite.
Palvella Therapeutics (NASDAQ:PVLA), ein klinisch t盲tiges Biopharmaunternehmen, das Therapien f眉r seltene genetische Hautkrankheiten entwickelt, hat bevorstehende Pr盲sentationen auf zwei gro脽en Investorenkonferenzen im Gesundheitsbereich angek眉ndigt. CEO Wes Kaupinen wird auf der Cantor Global Healthcare Conference am 4. September 2025 um 14:45 Uhr ET und auf der H.C. Wainwright Global Investment Conference am 8. September 2025 um 10:30 Uhr ET pr盲sentieren.
Die Pr盲sentationen werden per Live-Webcast auf der Palvella-Website verf眉gbar sein; Wiederholungen stehen anschlie脽end f眉r etwa 90 Tage zur Verf眉gung.
- None.
- None.
WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of聽Palvella, will present at two upcoming healthcare investor conferences. The details are as follows:
Cantor聽Global Healthcare Conference
Thursday, September 4, 2025, at 2:45pm ET
H.C. Wainwright 27th Annual Global Investment Conference
Monday, September 8, 2025, at 10:30am ET
A live webcast of both presentations will be available on the聽聽section of Palvella's website at聽. An archived replay of the webcast will be available for approximately 90 days following the presentation.
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN鈩� platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella鈥檚 lead product candidate, QTORIN鈩�
颁辞苍迟补肠迟听滨苍蹿辞谤尘补迟颈辞苍
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
FAQ
When is Palvella Therapeutics (PVLA) presenting at the Cantor Global Healthcare Conference 2025?
When is PVLA's presentation at the H.C. Wainwright Conference 2025?
How can investors access Palvella Therapeutics' conference presentations?
What is Palvella Therapeutics' (PVLA) main business focus?
